רווח תפעולי לפני ניכוי פחת: affimed.com (AFMD)

Affimed minimizes capital expenditures through biomanufacturing outsourcing. The EBITDA timeline on GURU.Markets reflects this strategy, where determines the current status of the parameter. Demand for lymphoma treatment renders the company independent of macro cycles, while the high barrier to entry in the immuno-oncology niche securely protects unique developments and retains the patient base.

This metric captures the actual cash flow from operating activities, excluding non-cash charges to identify real operational efficiency and the cyclicality of inflows. By analyzing the overall EBITDA of the organization, an investor can assess the ability of Affimed (AFMD) to fund the development race for NK-cell drugs amidst fierce competition with CAR-T therapy, ensuring they avoid overpaying for the asset during temporary peaks.